Jazz Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for JAZZ PHARMS, and what generic alternatives to JAZZ PHARMS drugs are available?
JAZZ PHARMS has four approved drugs.
There are forty-two US patents protecting JAZZ PHARMS drugs.
There are one hundred and ninety-one patent family members on JAZZ PHARMS drugs in twenty-eight countries and sixty-seven supplementary protection certificates in eight countries.
Summary for Jazz Pharms
| International Patents: | 191 |
| US Patents: | 42 |
| Tradenames: | 4 |
| Ingredients: | 4 |
| NDAs: | 4 |
Drugs and US Patents for Jazz Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jazz Pharms Res | EPIDIOLEX | cannabidiol | SOLUTION;ORAL | 210365-001 | Sep 28, 2018 | RX | Yes | Yes | 9,956,186 | ⤷ Subscribe | ⤷ Subscribe | ||||
| Jazz Pharms Res | EPIDIOLEX | cannabidiol | SOLUTION;ORAL | 210365-001 | Sep 28, 2018 | RX | Yes | Yes | 10,709,673 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Jazz Pharms Inc | DEFITELIO | defibrotide sodium | SOLUTION;INTRAVENOUS | 208114-001 | Mar 30, 2016 | RX | Yes | Yes | 11,746,348 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Jazz Pharms | XYREM | sodium oxybate | SOLUTION;ORAL | 021196-001 | Jul 17, 2002 | RX | Yes | Yes | 8,772,306*PED | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Jazz Pharms Inc | DEFITELIO | defibrotide sodium | SOLUTION;INTRAVENOUS | 208114-001 | Mar 30, 2016 | RX | Yes | Yes | 11,085,043 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Jazz Pharms Res | EPIDIOLEX | cannabidiol | SOLUTION;ORAL | 210365-001 | Sep 28, 2018 | RX | Yes | Yes | 12,064,399 | ⤷ Subscribe | ⤷ Subscribe | ||||
| Jazz Pharms Res | EPIDIOLEX | cannabidiol | SOLUTION;ORAL | 210365-001 | Sep 28, 2018 | RX | Yes | Yes | 11,446,258 | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Jazz Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Jazz Pharms | LUVOX CR | fluvoxamine maleate | CAPSULE, EXTENDED RELEASE;ORAL | 022033-001 | Feb 28, 2008 | 7,465,462 | ⤷ Subscribe |
| Jazz Pharms Res | EPIDIOLEX | cannabidiol | SOLUTION;ORAL | 210365-001 | Sep 28, 2018 | 10,195,159 | ⤷ Subscribe |
| Jazz Pharms | LUVOX CR | fluvoxamine maleate | CAPSULE, EXTENDED RELEASE;ORAL | 022033-002 | Feb 28, 2008 | 7,465,462 | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for JAZZ PHARMS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Capsules | 100 mg | ➤ Subscribe | 2009-04-20 |
| ➤ Subscribe | Extended-release | 150 mg | ➤ Subscribe | 2009-04-13 |
| ➤ Subscribe | Oral Solution | 500 mg/mL | ➤ Subscribe | 2010-07-08 |
International Patents for Jazz Pharms Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| United Kingdom | 2531281 | ⤷ Subscribe |
| Mexico | 2020011163 | ⤷ Subscribe |
| New Zealand | 765231 | ⤷ Subscribe |
| Canada | 2902948 | ⤷ Subscribe |
| Australia | 2015332208 | ⤷ Subscribe |
| Canada | 2952858 | ⤷ Subscribe |
| South Korea | 20190112197 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Jazz Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2203431 | CA 2015 00014 | Denmark | ⤷ Subscribe | PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150115 |
| 2465580 | SPC/GB21/030 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: CABOTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, INCLUDING CABOTEGRAVIR SODIUM.; REGISTERED: UK EU/1/20/1481 (NI) 20201221; UK PLGB 35728/0055-57 20201221 |
| 0579826 | SPC/GB02/042 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: ERTAPENEM ((1R,5S,6S,8R,2'S,4'S)-2-(2-(3-CARBOXYPHENYLCARBAMOYL)PYRROLIDIN-4-YLTHIO)-6-(1-HYDROXYETHYL)-1-METHYLCARBAPENEM-3-CARBOXYLIC ACID), A PHARMACEUTICALLY ACCEPTABLE SALT OR IN VIVO HYDROLYSABLE ESTER THEREOF, ESPECIALLY AS THE MONOSODIUM SALT ERTA; REGISTERED: UK EU/1/02/216/001 20020422 |
| 0145340 | 99C0005 | Belgium | ⤷ Subscribe | PRODUCT NAME: FOSPHENYTOIN DISODIUM; NAT. REGISTRATION NO/DATE: NL 23 613 19980806; FIRST REGISTRATION: GB - PL 000 19/0157 19980204 |
| 2203431 | 92666 | Luxembourg | ⤷ Subscribe | PRODUCT NAME: DASABUVIR OU UN SEL QUI EN DERIVE, Y COMPRIS DASABUVIR SODIUMMONOHYDRATE. FIRST REGISTRATION: 20150119 |
| 2203431 | 15C0013 | France | ⤷ Subscribe | PRODUCT NAME: DASABUVIR OU UN SEL DE CELUI-CI, NOTAMMENT LE SEL DE SODIUM; REGISTRATION NO/DATE: EU/1/14/983 20150119 |
| 2932970 | 18C1043 | France | ⤷ Subscribe | PRODUCT NAME: UNE COMBINAISON COMPRENANT DU DOLUTEGRAVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI,EN PARTICULIER LE SEL DE SODIUM DU DOLUTEGRAVIR,ET DE LA RILPIVIRINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI,EN PARTICULIER LE CHLORHYDRATE DE RILPIVIRINE; REGISTRATION NO/DATE: EU/1/18/1282 20180518 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
